$1.34
0.032.29%
At Close: -
$1.34
00.00%
After Hours: 4:02 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Aclaris Therapeutics (NASDAQ:ACRS) Stock, Analyst Ratings, Price Targets, Forecasts
Aclaris Therapeutics Inc has a consensus price target of $14.67 based on the ratings of 7 analysts. The high is $22 issued by Evercore ISI Group on October 3, 2023. The low is $1 issued by Stifel on December 18, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stifel, and HC Wainwright & Co. on December 29, 2023, December 18, 2023, and November 14, 2023, respectively. With an average price target of $6.33 between HC Wainwright & Co., Stifel, and HC Wainwright & Co., there's an implied 372.64% upside for Aclaris Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Evercore ISI Group
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Aclaris Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/22/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 01/22/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 01/11/2024 | Buy Now | — | BTIG | Julian Harrison | — | Downgrade | Buy → Neutral | Get Alert |
| 12/29/2023 | Buy Now | 571.64% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | -25.37% | Stifel | Alex Thompson | $2 → $1 | Maintains | Hold | Get Alert |
| 11/14/2023 | Buy Now | 571.64% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $9 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Downgrade | Overweight → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 49.25% | Stifel | Alex Thompson | $20 → $2 | Downgrade | Buy → Hold | Get Alert |
| 11/13/2023 | Buy Now | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/09/2023 | Buy Now | 2735.82% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 10/04/2023 | Buy Now | 3108.96% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 1541.79% | Evercore ISI Group | Gavin Clark-Gartner | → $22 | Initiates | → Outperform | Get Alert |
| 09/19/2023 | Buy Now | 2735.82% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | Buy Now | 3108.96% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 1392.54% | Stifel | Alex Thompson | $16 → $20 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 3108.96% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 3108.96% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2023 | Buy Now | 1467.16% | Goldman Sachs | Corinne Jenkins | $25 → $21 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 2064.18% | BTIG | Julian Harrison | $32 → $29 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 3108.96% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $43 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 3631.34% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | 2735.82% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | → Overweight | Get Alert |
| 12/14/2022 | Buy Now | 2064.18% | Stifel | Alex Thompson | → $29 | Initiates | → Buy | Get Alert |
| 12/01/2022 | Buy Now | 1765.67% | Goldman Sachs | Corinne Jenkins | → $25 | Initiates | → Buy | Get Alert |
| 10/06/2022 | Buy Now | 2288.06% | BTIG | Julian Harrison | → $32 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Aclaris Therapeutics (ACRS) stock?
The latest price target for Aclaris Therapeutics (NASDAQ:ACRS) was reported by HC Wainwright & Co. on July 22, 2024. The analyst firm set a price target for $0.00 expecting ACRS to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ:ACRS) was provided by HC Wainwright & Co., and Aclaris Therapeutics reiterated their neutral rating.
When was the last upgrade for Aclaris Therapeutics (ACRS)?
There is no last upgrade for Aclaris Therapeutics
When was the last downgrade for Aclaris Therapeutics (ACRS)?
The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $0.00. The current price Aclaris Therapeutics (ACRS) is trading at is $1.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.